Eagle Pharmaceuticals (NASDAQ:EGRX) had its price objective lowered by equities research analysts at Mizuho to $52.00 in a research report issued to clients and investors on Wednesday, The Fly reports. The brokerage currently has a “neutral” rating on the specialty pharmaceutical company’s stock. Mizuho’s price objective points to a potential downside of 1.40% from the company’s previous close.
EGRX has been the subject of a number of other reports. ValuEngine upgraded shares of Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, July 10th. Zacks Investment Research upgraded shares of Eagle Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 9th. BidaskClub upgraded shares of Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, September 29th. TheStreet upgraded shares of Eagle Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Thursday, August 9th. Finally, Cantor Fitzgerald lowered shares of Eagle Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research report on Thursday, November 1st. One analyst has rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $77.17.
Shares of EGRX traded up $0.72 during mid-day trading on Wednesday, reaching $52.74. 7,586 shares of the stock traded hands, compared to its average volume of 337,974. The firm has a market capitalization of $761.61 million, a P/E ratio of 15.62 and a beta of 1.72. The company has a debt-to-equity ratio of 0.20, a current ratio of 5.59 and a quick ratio of 5.38. Eagle Pharmaceuticals has a 1 year low of $46.88 and a 1 year high of $85.66.
Eagle Pharmaceuticals (NASDAQ:EGRX) last released its quarterly earnings results on Thursday, November 1st. The specialty pharmaceutical company reported $1.18 EPS for the quarter, beating analysts’ consensus estimates of $0.91 by $0.27. The firm had revenue of $51.34 million during the quarter, compared to analyst estimates of $52.70 million. Eagle Pharmaceuticals had a net margin of 13.92% and a return on equity of 17.62%. The business’s revenue for the quarter was down 18.5% on a year-over-year basis. During the same period in the previous year, the business earned $1.22 EPS. On average, analysts expect that Eagle Pharmaceuticals will post 1.96 earnings per share for the current year.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Itau Unibanco Holding S.A. bought a new stake in shares of Eagle Pharmaceuticals during the 2nd quarter worth $108,000. Macquarie Group Ltd. lifted its holdings in shares of Eagle Pharmaceuticals by 400.0% during the 2nd quarter. Macquarie Group Ltd. now owns 1,500 shares of the specialty pharmaceutical company’s stock worth $113,000 after acquiring an additional 1,200 shares during the last quarter. Acadian Asset Management LLC bought a new stake in shares of Eagle Pharmaceuticals during the 3rd quarter worth $115,000. Meeder Asset Management Inc. lifted its holdings in shares of Eagle Pharmaceuticals by 232.6% during the 2nd quarter. Meeder Asset Management Inc. now owns 1,866 shares of the specialty pharmaceutical company’s stock worth $141,000 after acquiring an additional 1,305 shares during the last quarter. Finally, Piedmont Investment Advisors LLC bought a new stake in shares of Eagle Pharmaceuticals during the 2nd quarter worth $150,000.
About Eagle Pharmaceuticals
Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).
Further Reading: Growth Stocks
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.